DRUG DISCOVERY SOLUTIONS

Drug Discovery & Pharmaceuticals

icon_drug_discovery

Enabling breakthroughs in Drug Discovery

Our targeted venom discovery arrays have been proven effective on hard-to-hit targets - offering new solutions where traditional approaches have failed.

The UK's largest venom library

Molecular & Therapeutic Targeted Arrays

Full Hit-to-Lead follow up

Why Venoms and Venomtech?

Animal venoms are a complex mix of peptides, small molecules and proteins that, activate, inhibit or otherwise modulate molecular targets such as ion channels, GPCRs and enzymes. Often they have exquisite potency and selectivity, possibly because they have been developed through millions of years of evolution, rather than a few hundred years of drug discovery. Animal venoms have not evolved to cure our diseases however, so why should they have any potential in drug discovery?

venom array

 

Conserved evolution: The targets that venoms have evolved to hit in their prey have also evolved in humans and may be highly conserved. For example, a Na+ ion channel vital for insect life has an orthologue in humans, which has evolved to be involved in pain transmission. Thus, because of conserved evolution, venom that evolved to kill insects can have potential as therapeutic agent in treating pain. In contrast, we also see venom activities that defy our current evolutionary understanding e.g. snake venom disintegrins that are antimetastatic but have not evolved to cure cancer.

 

Known mechanisms of action: Many venoms have actions on their prey that are desirable for treating specific diseases. e.g. snake venoms that lower blood pressure have potential in treating hypertension, and spider venoms that can block pain receptors.

 

Venom derived drugs already in the clinic: To date there are 15 venom-derived drugs marketed (several with peak sales >$0.5B) and >14 new compounds in clinical trials. Such successes include the first ever anti-hypertenisve Captopril, and it’s successors. Snake venom from the Fer-de-Lance inspired researchers to investigate how this snake caused extreme hypotension in its victims. Using the snake venom peptide as a tool lead to the connection of angiotensin and blood pressure, thus the ACE inhibitor series of compounds were launched, saving millions of lives. Other successes have been in clot busters such as Integrilin from rattlesnakes and a glucagon like peptide from Gila monster venom.

Molecular & Therapeutic Targeted Arrays for Drug Discovery

Ion channel venoms

Ion Channels

New approaches to ion-channel pathways

GPCR's venom

GPCRs

Our peptides are unlocking GPCR targets in many applications

Kinases venom

Kinases

Our peptides are providing solutions for research into Kinases

Epigenetics venom

Epigenetics

Effective solutions for hard-to-hit epigenetic targets

Antimicrobial resistance venom

Antimicrobial Resistance

Our peptides are natural solutions for modulating resistant entities and controlling pests

S100 proteins venom

S100 Proteins

We are hitting S100 targets

Drug Discovery Resources

Papers and posters venom

Papers & Posters

Helpful publications from our team, our partners and key industry sources

News and events venom

News & Events

Up-to-date events and news items about the species, the science and our team

People and partners venom

People & Partners

Find out more about our core and extended team, get in touch, collaborate!